Search
Recombinant Super-Compound Interferon
go.drugbank.com/drugs/DB15752InvestigationalRecombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.
Afimetoran
go.drugbank.com/drugs/DB16580Investigational[L32018, L32023] It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male … Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8.
Streptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16710ApprovedInvestigationalIt is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
Garlic oil
go.drugbank.com/drugs/DB15989InvestigationalCategories: Compounds used in a research, industrial, or household settingBenzquinamide
go.drugbank.com/drugs/DB00767ApprovedWithdrawnBenzquinamide is a discontinued antiemetic compound with antihistaminic, mild anticholinergic, and sedative properties. … The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.
IR502
go.drugbank.com/drugs/DB06463ExperimentalIR502 (Zorcell) is a potential treatment for psoriasis.
TH0318
go.drugbank.com/drugs/DB05145ExperimentalTH0318 is a stabilized analogue of human GLP-1 (glucagon-like peptide-1) under investigation for the treatment of type 2 diabetes.
Tin protoporphyrin IX
go.drugbank.com/drugs/DB16449InvestigationalSynonyms: Tin protoporphyrin IX, TIN, (DIHYDROGEN PROTOPORPHYRIN IX-ATO(2-))-BTA9881
go.drugbank.com/drugs/DB05226InvestigationalBTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.